Zebrafish Oncology Platform

ZebraOncoFish

Based on our long track on research investment, we have created ZebraONCOfish. This platform allows to act in the pre-clinical stages of drug development and makes personalized medical care for cancer treatment possible.

The ZebraONCOfish platform contains 3 main pillars:

  • A multi-cancer library primary isolated from patients, which is being used to perform cancer cell cultures.
  • Drug screening and personalized medicine services, evaluating treatment’s efficacy on in vivo patient avatars.
  • Development and implementation of next-generation new anti-cancer drugs, and the continuously improvement of our platform.

 

The bridge connecting these 3 pillars is our animal model, zebrafish.

Treatment

New Molecules

 

 

Biobank

Cytotoxicity

Energy metabolism assays

Cell viability assays

Cell antiproliferative assays

In vitro
efficacy

Cell migration

and invasion assays 

In vivo
toxicity

Acute toxicity

Developmental toxicity

Cardiotoxicity

In vivo
efficacy

Zebrafish embryo

xenograft assays

Treatment

New Molecules

 

 

Biobank

Cytotoxicity

Energy metabolism assays

Cell viability assays

Cell antiproliferative assays

Treatment

New Molecules

 

 

Biobank

In vitro
efficacy

Cell migration

and invasion assays 

Treatment

New Molecules

 

 

Biobank

In vivo
toxicity

Acute toxicity

Developmental toxicity*

Cardiotoxicity*

Treatment

New Molecules

 

 

Biobank

In vivo
efficacy

Zebrafish embryo

xenograft assays

Aplications

  • Drug discovery and development: test drug efficacy using our biobank.
  • Safety and toxicity: evaluate your compound´s safety and toxicity profiles with the only patient-derived in vitro and in vivo model that can be developed from multi-cancer library primary isolated from patients.
  • Personalized medicine: ZebraONCOfish allows to create colon cancer patient avatars to design targeted and personalized therapies.
  • Clinical Database: we are creating an important Database with general patient information, characteristics of the tumor, molecular characterización, in vitro assays and in vivo assays.

Biobank - Biopsy Library

Ikan Biotech offer our clients and collaborators access to a biobank of:

  • Tumor cells culture isolated from patients
  • Fresh cancer patient biopsy
  • Stable cancer cell lines

 

This multi-cancer library can be applied in different areas, including:

  • Oncology
  • Antitumor drug screening
  • Immuno-oncology
  • Drug safety and toxicology

Clinical Data Base

Thanks to the use of our Zebraoncofish platform, we are generating an important database that contains the following parameters for each assay carried out:

General data of the patient

Demographic information (gender, ethnicity, age).

Anthropometric measurements (height, weight).

Risk factors (metabolic, chemical, disease).

 

Characteristics of the tumor

Diagnosis, tumor stage, metastasis.

Histopathological information (pathological diagnostic method, histological characteristics, immunohistochemical markers).

Tumor type (location, growth pattern).

Molecular, genetic and epigenetic alterations.

Treatment (type of treatment administered, date of treatment and response).

Recurrence.

Survival (last medical visit, date of death).

 

Molecular characterization based on NGS (Next Generation Sequencing)

Characterization of 500 genes in addition to MSI and TMB values ​​with clinical validity of tumor cells.

 

In vitro tests

Results of viability, proliferation and metabolism of tumor cells in contact with different treatments.

Gene expression of cells in response to different concentrations or combinations of treatments through RT-PCR.

 

In vivo tests (zebrafish)

Measurements from templates transfected with GFP.

Gene expression of tumor markers.

Data from histological analysis and imaging.

RNA and cDNA extraction data.